Contineum Therapeutics, Inc. (CTNM)

Contineum Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-35.46	22.72	-24.25	-29
Depreciation & Amortization	0.22	0.2	0.33	0.33
Other Amortization	-	-	-	0.15
Loss (Gain) From Sale of Assets	-0.02	-	0	-
Loss (Gain) From Sale of Investments	-4.08	-2.66	0.25	0.39
Stock-Based Compensation	5.31	2.22	1.93	1.75
Other Operating Activities	1.09	-2.11	2.9	0.01
Change in Accounts Payable	0.14	-	-0.23	-0.11
Change in Other Net Operating Assets	-0.54	-1.02	-1.04	0.22
Operating Cash Flow	-33.35	19.35	-20.12	-26.27
Capital Expenditures	-0.66	-0.41	-0.12	-0.17
Investment in Securities	-50.68	-65.15	22.42	-64.8
Investing Cash Flow	-51.32	-65.57	22.3	-64.97
Long-Term Debt Repaid	-	-3.75	-1.25	-
Net Debt Issued (Repaid)	-	-3.75	-1.25	-
Issuance of Common Stock	108.41	0.16	0.02	0.11
Repurchase of Common Stock	-0.03	-0.03	-0	-
Other Financing Activities	-0.34	-0.34	-	-
Financing Cash Flow	108.04	56.18	-1.24	79.84
Net Cash Flow	23.37	9.96	0.94	-11.4
Free Cash Flow	-34	18.94	-20.24	-26.43
Free Cash Flow Margin	-	37.87%	-	-
Free Cash Flow Per Share	-2.52	5.58	-9.02	-12.53
Cash Interest Paid	0.15	0.15	0.23	0.22
Cash Income Tax Paid	0.45	0.45	-	-
Levered Free Cash Flow	-22.27	13.08	-12.61	-
Unlevered Free Cash Flow	-22.27	13.21	-12.37	-
Change in Net Working Capital	-0.05	-1.17	0.31	-

Source: S&P Capital IQ. Standard template. Financial Sources.